Advaxis, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing its proprietary Listeria monocytogenes (Lm) technology for antigen delivery products, primarily in the United States. Its pipeline includes ADXS-PSA, currently in Phase 2 clinical trials for metastatic prostate cancer; ADXS-503, undergoing Phase 1/2 clinical trials for non-small cell lung cancer; and ADXS-504, aimed at treating prostate cancer. The company is also advancing Lm Technology immunotherapies through clinical studies in broader disease areas, such as hotspot/off-the-shelf neoantigen-directed therapies, human papilloma virus-associated cancers, and prostate cancer.